On Wednesday, World Health Organisation (WHO) said it expects to receive clarifications from Bharat Biotech by the end of this week on its COVID-19 vaccine, Covaxin and will meet on November 3 for a final risk-benefit assessment for the Emergency Use Listing.

• The 5 index signals smart traders watch before placing a single order
• Kwality Pharma Hits 52-Week High After Record FY26 Revenue
• Jay Bharat Maruti Hits 20% Upper Circuit on 287% Profit Surge
• ZEEL Falls 6% After Q4 Swings to Net Loss on Ad Revenue Miss
• Overnight Stock Market Movements: Key Developments 

WHO Technical Advisory Group for Emergency Use Listing (EUL) is an independent advisory group that provides recommendations to WHO on whether a #COVID19 vaccine can be listed for emergency use under the EUL procedure, the WHO tweeted.

The Technical Advisory Group met on October 26 and decided that additional clarifications from the manufacturer (Bharat Biotech) are needed to conduct a final EUL risk-benefit assessment for global use of the Covaxin vaccine”.

The Technical Advisory Group expects to receive these clarifications from the manufacturer (Bharat Biotech) by the end of this week. It aims to reconvene for the final risk-benefit assessment on Wednesday, November 3, 2021, the WHO tweeted.